RCRasha Charrouf

Rasha Charrouf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rasha Charrouf has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial

    by Evelyn B. Parr, Rasha Charrouf, Amy T. Hutchison, Steve A. Flint, Xiao Tong Teong, Andrew D. Vincent, Ana Paula Bravo-Garcia, Zoe Siviour, Gary A. Wittert, Leah Brennan, et al.

    Aims/hypothesis: Time-restricted eating (TRE) consolidates daily energy intake to a consistent 6–10 h window. The aim was to assess whether TRE is non-inferior to individualised dietetic guidance (IDG) in changing HbA 1c at 4 months in adults at risk of type 2 diabetes. Methods: In a two-arm, parallel-group, multi-centre randomised, non-inferiority clinical trial at two Australian clinical research institutes, adults at risk of type 2 diabetes (i.e. with overweight or obesity and a score of ≥15 on the Australian type 2 diabetes risk assessment tool) were recruited. Participants were randomly assigned using an electronic system (1:1) to TRE (9 h, self-selected eating window, last eating occasion by 19:00 hours) or IDG. Staff conducting assessments and analyses were blinded to allocation; participants and dietitians were unblinded. Both groups received five personalised telehealth consultations between 0 and 3 months (3 h total), specific to their allocated group. The primary outcome was the between-group difference for change in HbA 1c at 4 months assessed via covariate linear regression using multiple imputation with a non-inferiority margin set at 1.1 mmol/mol (0.10%). Secondary outcomes were change in HbA 1c at 12 months and changes in fasting glucose, insulin, HOMA-IR and nocturnal glucose AUC. Exploratory outcomes included changes in cardiometabolic outcomes and body mass and composition. Adverse events were tracked for 12 months. Results: One hundred and twenty four participants were randomised to TRE and 123 to IDG (mean ± SD HbA 1c : 40 ± 3 mmol/mol [5.8 ± 0.3%]). At 4 months, TRE was non-inferior but not superior to IDG for HbA 1c (mean [95% CI]: −0.22 [−0.72, 0.30] mmol/mol; −0.02 [−0.07, 0.03]%; p =0.40). At 12 months, the upper bound of the difference between groups was larger than the non-inferiority margin (0.10%) meaning that non-inferiority could no longer be concluded (mean [95% CI]: 0.47 [−0.19, 1.23] mmol/mol; 0.05 [−0.02, 0.11]%; p =0.14). However, the absolute changes in HbA 1c were small and not clinically meaningful in either group at either time point. Adverse events were minor and not different between interventions. Conclusions/interpretation: TRE may offer a pragmatic and practical short-term alternative when access to dietetic support is limited, or if the approach is preferred by an individual. Trial registration: ClinicalTrials.gov; NCT04762251 Funding: This research was funded by the Australian Government Medical Research Future Fund (MRFF 1200555).